Hjem › Non-Hodgkin lymfom
Non-Hodgkin lymfom kliniske forsøg rekrutterer i USA
127 studier for Non-Hodgkin lymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX31 studier
- New York City, NY31 studier
- Boston, MA26 studier
- Nashville, TN21 studier
- Philadelphia, PA20 studier
- Baldwin Park, CA19 studier
- Atlanta, GA18 studier
- Chicago, IL18 studier
- Columbus, OH18 studier
- Milwaukee, WI18 studier
- Washington, DC18 studier
- Dallas, TX17 studier
- Durham, NC16 studier
- Seattle, WA16 studier
- Portland, OR15 studier
- Rochester, MN14 studier
- Miami, FL14 studier
- Omaha, NE14 studier
- Denver, CO14 studier
- Cleveland, OH13 studier
- Salt Lake City, UT13 studier
- Mountain View, CA12 studier
- St. Louis, MO11 studier
- Aurora, CO11 studier
- Los Angeles, CA9 studier
- Tampa, FL9 studier
- Jacksonville, FL9 studier
- Cincinnati, OH9 studier
- San Francisco, CA9 studier
- Pittsburgh, PA8 studier
- San Diego, CA8 studier
- Baltimore, MD8 studier
- Ann Arbor, MI8 studier
- Cedar Rapids, IA8 studier
- Clifton, NJ7 studier
- Buffalo, NY7 studier
- Kansas City, MO7 studier
- Edison, NJ7 studier
- Birmingham, AL7 studier
- Queens, NY7 studier
Efter delstat
- Alabama7 studier
- Arizona14 studier
- Arkansas5 studier
- Californien42 studier
- Colorado20 studier
- Connecticut8 studier
- Delaware4 studier
- District of Columbia4 studier
- Florida32 studier
- Georgia21 studier
- Hawaii3 studier
- Idaho3 studier
- Illinois20 studier
- Indiana10 studier
- Iowa10 studier
- Kansas9 studier
- Kentucky5 studier
- Louisiana6 studier
- Maine4 studier
- Maryland21 studier
- Massachusetts28 studier
- Michigan13 studier
- Minnesota19 studier
- Mississippi3 studier
- Missouri10 studier
- Montana3 studier
- Nebraska15 studier
- New Jersey13 studier
- New Mexico4 studier
- New York40 studier
- North Carolina24 studier
- North Dakota3 studier
- Ohio34 studier
- Oklahoma3 studier
- Oregon15 studier
- Pennsylvania26 studier
- Rhode Island5 studier
- South Carolina5 studier
- South Dakota3 studier
- Tennessee24 studier
- Texas48 studier
- Utah14 studier
- Virginia13 studier
- Washington20 studier
- West Virginia3 studier
- Wisconsin20 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RekruttererFase 1
Op til 75 år · Alle køn · Opdateret 2. okt. 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RekruttererFase 1
Alder 12 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RekruttererFase 1
Alder 12 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RekruttererFase 1/2
Alder 3 til 39 · Alle køn · Opdateret 30. sep. 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RekruttererObservationsstudie
Alder 18 til 120 · Alle køn · Opdateret 28. sep. 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RekruttererFase 1/2
Alder 18 til 120 · Alle køn · Opdateret 28. sep. 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
RekruttererFase 2
Alder 18 til 120 · Alle køn · Opdateret 25. sep. 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RekruttererFase 1
Alder 18 til 100 · Alle køn · Opdateret 15. sep. 2026 · NCT05798897Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.